For safety and efficacy in targeted abdominal MR Imaging

News and clinical trends

The number of treatment methods and the effectiveness of the treatments for liver malignancies are increasing. Therefore the demand for better diagnostic methods is also increasing.
CMC 001 has the potential to take a position as the primary screening product for known or suspected focal liver lesions.

Summary

Liver imaging trends

  • There is currently a strong trend towards more active liver surgery in patients with malignant liver disease. This requires more accurate diagnosis for optimal patient treatment, including:
    - Number of tumours
    - Size of tumours
    - Localization of tumours
    - Delineation of tumours
  • The safety of contrast media is currently in focus
    Clinical studies show that MRI liver imaging with CMC 001 meet both diagnostic and safety challenges

 
Contact us

Klick here to contact us

Benefits for your team

Using CMC 001 creates advantages for the staff, and saves time and cost.

More Benefits
Medical background

CMC 001 delivers manganese orally, resulting in excellent liver enhancement in MRI.

Medical background
About CMC Contrast

100% owned and financed by professional venture capital companies specializing in life sciences and dedicated to contrast agents

Learn more
CMC Contrast AB, Ideon, SE-223 70 Lund. Telephone +46 46 286 37 60. E-mail: info@cmc-contrast.se